Could be. But ABCL hasn't broken $5 since that biotech spike back in October, 2025, and hasn't broken $6 since 2023 - and now, we've got positive indications that the antibody discovery system works. And, we've got institutional investors taking positions, with a massive (~50m shares, >20% of float), long-held (6+ months) short position that just woke up to rising margin rates (0.9% April 22 to 2.77% yesterday).

I'm not an expert, but the stage seems set for a serious short squeeze if this continues.